What is Sermorelin?
A lab-made copy of the active front part of the body's own growth-hormone-releasing hormone, originally made as an injectable prescription drug.
US legal status
Open question
Whether a 503A pharmacy may use sermorelin as a component of an approved drug, now that the approval of that drug, GEREF, has been withdrawn, is not settled. The FDA has not addressed it for 503A pharmacies in any source we read.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
On the FDA label
- The GEREF label listed a reaction where the drug was injected (pain, swelling or redness) as the most common, in about 1 in 6 patients. 3 of 350 patients stopped because of it.1213
- The GEREF label listed headache, flushing, trouble swallowing (dysphagia), dizziness, hyperactivity, sleepiness (somnolence) and hives (urticaria), each in under 1% of patients.12
- The GEREF label reported hypothyroidism in 6.5% of patients in trials, and advised thyroid tests before and during treatment.1213
- The GEREF label said many patients developed antibodies to GRF, of unclear significance, and that allergic reactions were possible.12
- The GEREF label said the drug was not studied in growth hormone deficiency caused by a lesion inside the skull, and placed it in Pregnancy Category C (the old system). Whether it passes into breast milk is not known.1213
- The GEREF label said IGF-1, growth hormone, phosphorus and alkaline phosphatase may rise, and that a physician experienced in growth hormone deficiency was to supervise treatment.12
- The label information gives a half-life of about 11 to 12 minutes. About 6% of the drug injected under the skin reaches the bloodstream.13
Reports to the FDA
- The FDA's adverse event database (FAERS, updated October 28, 2026) holds 69 reports that mention sermorelin. The most frequent terms include itching (pruritus), trouble swallowing, hypersensitivity, nausea and anaphylactic reaction (4 reports); the reports are not checked, and they do not show that sermorelin caused the event.14
- Sleepiness (somnolence) is listed in under 1% of patients on the GEREF label, and appears in 1 FAERS report.1252
- Hair loss is not on the GEREF label's list of adverse reactions. None of the 183 reaction terms in the FAERS reports on sermorelin is alopecia.1252
- Of the FAERS reports on sermorelin, 45 are coded as serious and 24 as not serious.52
- In FAERS, 41 reports on sermorelin are coded as from the US, and the rest are not.52
- None of the 183 reaction terms in the FAERS reports on sermorelin is a neoplasm, cancer, carcinoma, tumor or lymphoma.52
What the FDA has said
No data
- We found no data on adults who take it long term for wellness, on pregnancy or breastfeeding, on forms taken by mouth (oral, ODT or troche), on people with a history of cancer, or on combination products.1112
- The cancer warnings on the labels of other growth-hormone drugs are not about sermorelin. We found no FDA or NIH statement on sermorelin and cancer.
Product quality
- The FDA found "research use only" sermorelin sold for human use and treated it as an unapproved new drug. We found no contamination or potency test data for compounded sermorelin.10
Compounded sermorelin is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
- 1.Federal Register 78 FR (2013-03-04), Doc 2013-04827, "Determination That GEREF (Sermorelin Acetate)… Not Withdrawn for Reasons of Safety or Effectiveness"Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 2.DrugFuture mirror of Drugs@FDA, GEREF recordsTier 1: regulator or registerdrugfuture.comread Nov 16, 2026↩
- 3.Federal Register 91 FR (2026-10-30), Doc 2026-22192, HHS interim enforcement discretion for 503A peptide compoundingTier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 4.Venable LLP, "HHS Announces Interim Enforcement Discretion…" (Nov 2026; lists Appendix A peptides)Tier 3: reference, law firm or pressvenable.comread Nov 16, 2026↩
- 5.FDA, "Bulk Drug Substances Used in Compounding Under Section 503A" (current as of 2026-05-14)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 6.FDA, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A" (updated 2026-05-14)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 7.FDA, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503B" (updated 2025-03-21)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.FDA, "Bulk Drug Substances Used in Compounding Under Section 503B" (current as of 2025-01-07)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.FDA, PCAC meeting notice, July 23-24 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 10.FDA Warning Letter, Xcel Research LLC, MARCS-CMS 694608 (2024-12-10)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 11.University of Maryland M-CERSI, "Summary Report: Sermorelin Acetate" (Dec 2020, FDA grant 5U01FD005946)Tier 2: peer-reviewed or trial registryarchive.hshsl.umaryland.eduread Nov 16, 2026↩
- 12.RxList, Sermorelin Acetate (label-derived; side effects and description)Tier 3: reference, law firm or pressrxlist.comread Nov 16, 2026↩
- 13.RxList, Sermorelin Acetate clinical pharmacologyTier 3: reference, law firm or pressrxlist.comread Nov 16, 2026↩
- 14.openFDA FAERS drug/event API, query medicinalproduct:"sermorelin" (last_updated 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 15.WADA Prohibited List (2026), S2.2.4Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
- 16.German Sport University Cologne, S2 prohibited class pageTier 3: reference, law firm or pressdshs-koeln.deread Nov 16, 2026↩
- 17.DEA Diversion, Controlled Substances, Alphabetical Order (footer 12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 18.PubMed 9005976, "Effects of single nightly injections of GHRH 1-29 in healthy elderly men," Metabolism 1997;46(1):89-96Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 19.Khorram O et al., JCEM 1997 (Nov), [Nle27]GHRH(1-29)-NH2 in aging men and women (via QxMD)Tier 2: peer-reviewed or trial registryread.qxmd.comread Nov 16, 2026↩
- 20.Walker RF, "Sermorelin: a better approach…?" Clin Interv Aging 2006;1(4):307-8 (editorial)Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026
- 21.Frier Levitt, "FL Peptides" (Jan 2026)Tier 3: reference, law firm or pressfrierlevitt.comread Nov 16, 2026
- 22.Portrait Care, "Is Sermorelin FDA Approved?"Tier 4: lead onlyportraitcare.comread Nov 16, 2026
- 23.Strut Health, Sermorelin pageTier 4: lead onlystruthealth.comread Nov 16, 2026
- 24.Bodybuilding Health+ (Dynamo Group LLC), Sermorelin pageTier 4: lead onlybbhealthplus.comread Nov 16, 2026
- 25.Invigor Medical, Sermorelin checkoutTier 4: lead onlytryinvigor.comread Nov 16, 2026
- 26.Empower Pharmacy, Sermorelin pageTier 4: lead onlyempowerpharmacy.comread Nov 16, 2026↩
- 27.HealingMaps, "Sermorelin is the FDA-Approved Peptide…"Tier 4: lead onlyhealingmaps.comread Nov 16, 2026
- 28.HealingMaps, "The 4 Best Sermorelin Programs Online in 2026"Tier 4: lead onlyhealingmaps.comread Nov 16, 2026
- 29.FDA Guidance, "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B" (Jan 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 30.Drugs@FDA, NDA 020443 overview (GEREF)Tier 1: regulator or registerFDAread Nov 16, 2026
- 31.Drugs@FDA, NDA 019863 overview (GEREF)Tier 1: regulator or registerFDAread Nov 16, 2026
- 32.FDA CDER, Approval Package NDA 19-863/S001 (approval letter 1991-08-26, chemist review, Serono letter)Tier 1: regulator or registerFDAread Nov 16, 2026
- 33.FDA approval letter, NDA 19-863/S-006 (Geref Diagnostic, Geriatric Use labeling, 2001)Tier 1: regulator or registerFDAread Nov 16, 2026
- 34.openFDA drugsfda API (NDA019863, NDA020443, BLA022505; ipamorelin and CJC-1295 searches return no records)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 35.Thorner M et al., Geref International Study Group, "Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children...", J Clin Endocrinol Metab 1996;81(3):1189-96. PMID 8772599Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 36.Prakash A, Goa KL, "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic GH deficiency", BioDrugs 1999;12(2):139-57. PMID 18031173Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 37.Corpas E et al., "GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men", J Clin Endocrinol Metab 1992;75(2):530-5 (NIA/NIH). PMID 1379256Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 38.Khorram O, Laughlin GA, Yen SS, "Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women", J Clin Endocrinol Metab 1997;82(5):1472-9. PMID 9141536Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 39.Neyzi O et al., "Growth response to GHRH(1-29)-NH2 compared with growth hormone", Acta Paediatr Suppl 1993;388:16-21. PMID 8329826Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 40.Wilton P et al., "Pharmacokinetics of GHRH(1-29)-NH2 ... after intravenous or intranasal administration", Acta Paediatr Suppl 1993;388:10-5. PMID 8329825Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 41.Pontiroli AE et al., "Effect of intranasal GHRH and CRH administration...", J Clin Endocrinol Metab 1989;68(4):821-4. PMID 2493480Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 42.Pinski J et al., "Comparison of GH-stimulation by GH-RH(1-29)NH2 ... intravenous, subcutaneous, intranasal ... pulmonary inhalation in rats", Int J Pept Protein Res 1993;41(3):246-9. PMID 8463048Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 43.Rafferty B et al., "hGRF1-29NH2: immunoreactive-GRF plasma levels after IV and SC administration", J Endocrinol 1985;107(3):R5-8. PMID 2866222Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 44.Soule S, King JA, Millar RP, "Incorporation of D-Ala2 in GHRH-(1-29)-NH2 increases the half-life ... in normal men", J Clin Endocrinol Metab 1994;79(4):1208-11. PMID 7962295Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 45.Esposito P et al. (Serono), "PEGylation of growth hormone-releasing hormone (GRF) analogues", Adv Drug Deliv Rev 2003;55(10):1279-91. PMID 14499707Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 46.Sigalos JT et al., "Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels", Am J Mens Health 2017;11(6):1752-7. PMID 28830317, PMC5675260Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 47.Guldner J et al., "Reduced efficacy of GHRH in modulating sleep endocrine activity in the elderly", Neurobiol Aging 1997;18(5):491-5. PMID 9390775Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 48.Murck H et al., "Longtime administration of GHRH does not restore ... sleep endocrine activity in 2 old-aged subjects", Pharmacopsychiatry 1997;30(4):122-4. PMID 9271777Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 49.Vitiello MV et al., "Growth hormone releasing hormone improves the cognition of healthy older adults", Neurobiol Aging 2006;27(2):318-23. PMID 16399214Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 50.Baker LD et al., "Effects of GHRH on cognitive function in adults with MCI and healthy older adults", Arch Neurol 2012;69(11):1420-9 (tesamorelin; NCT00257712). PMID 22869065Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 51.ClinicalTrials.gov API v2, query.intr=sermorelin (27), query.term=sermorelin (42), query.term=GEREF (2), plus study records NCT00000380, NCT01410799, NCT00807365, NCT00791843, NCT02553603, NCT00850564Tier 1: regulator or registerNLM/NIHread Nov 16, 2026↩
- 52.
- 53.EGRIFTA SV (tesamorelin) prescribing information, SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224 (effective 2026-07-29), via openFDA label API / DailyMedTier 1: regulator or registerFDA/NLMread Nov 16, 2026
- 54.EGRIFTA WR (tesamorelin) prescribing information, SPL set id 839334d3-8c1d-4c26-9036-2ab524a6ea75 (effective 2026-07-29)Tier 1: regulator or registerFDA/NLMread Nov 16, 2026
- 55.Drugs@FDA, BLA 022505 overview (EGRIFTA family; approval and supplement history)Tier 1: regulator or registerFDAread Nov 16, 2026
- 56.FDA supplement approval letter BLA 022505/S-020, Egrifta WR (2025-03-25)Tier 1: regulator or registerFDAread Nov 16, 2026
- 57.EGRIFTA (2 mg/vial) label, BLA 022505 S-010 ("Revised: 11/2018")Tier 1: regulator or registerFDAread Nov 16, 2026
- 58.GENOTROPIN (somatropin) prescribing information, SPL set id ffebf88b-d257-4542-9808-74d9b7167765 (effective 2026-08-04), via openFDA label APITier 1: regulator or registerFDA/NLMread Nov 16, 2026
- 59.openFDA drugsfda API, generic_name "somatropin" (6 applications with original approval dates)Tier 1: regulator or registerFDAread Nov 16, 2026
- 60.FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 04/22/2026)Tier 1: regulator or registerFDAread Nov 16, 2026
- 61.USADA, "Athlete Advisory: What's New on the 2027 WADA Prohibited List?"Tier 1: regulator or registerUSADAread Nov 16, 2026
- 62.DailyMed web services, spls.json?drug_name=sermorelin and drug_name=geref (0 results, db published 2026-11-13)Tier 1: regulator or registerNLMread Nov 16, 2026
- 63.PubMed E-utilities searches: sermorelin[tiab] (25 records); "(sermorelin OR GHRH-(1-29)) AND (oral OR sublingual) AND human" (17 records, none an oral sermorelin bioavailability study in humans)Tier 1: regulator or registerNLM/NIHread Nov 16, 2026
- 64.Brinkman JE et al., "Physiology, Growth Hormone", StatPearls (NCBI Bookshelf NBK482141; PMID 29489209; marked Archived, 2023), abstract read via Europe PMC because NCBI returned a captchaTier 2: peer-reviewed or trial registryNIH/NLM Bookshelfread Nov 16, 2026
- 65.Federal Register API, documents search `conditions[term]=sermorelin` (34 results, newest 2023-01-26) and `conditions[term]=peptide compounding` from 2026-10-30Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.